Respiratory Syncytial Virus Diagnostic Market
Respiratory Syncytial Virus Diagnostic Market Size, Share & Trends Analysis Report by Product (Kits and Assays, Instruments), by Method (Rapid Antigen Detection Tests, Molecular Diagnostics, Direct Fluorescent Antibody Method, Immunoassays and Others), and by End-Users (Hospitals, Clinics, and Laboratories), Forecast Period (2023-2030)
Respiratory syncytial virus diagnostic market is anticipated to grow at a significant CAGR of 6.5% during the forecast period (2023-2030). Rising incidence rates of respiratory illnesses, increasing newborn populations, an expanding need for in-vitro diagnostics, and rising demand for point-of-care facilities are a few of the main reasons propelling market expansion. According to a National Institute of Health (NIH) report published in November 2022, 90.0% of children get RSV within the first two years of life, and adults and older children frequently get it again. The majority of RSV patients will experience upper respiratory sickness, but a sizeable proportion will also experience lower respiratory illness, primarily bronchiolitis. For instance, in July 2023, US approved Beyfortus (nirsevimab), Manufactured by AstraZeneca and Sanofi, for the treatment of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns, infants, and children up to 24 months old who were born during or just beginning their first RSV season.
Segmental Outlook
The global respiratory syncytial virus diagnostic market is segmented on the product, method, and end-users. Based on the product, the market is sub-segmented into kits and assays, and instruments. Based on the method, the market is sub-segmented into rapid antigen detection tests, molecular diagnostics, direct fluorescent antibody methods, immunoassays, and others. Further, on the basis of end-users, the market is sub-segmented into hospitals, clinics, and laboratories. Among the products, the kits and assay sub-segment is anticipated to hold a considerable share of the market owing to the increase in the development of a fluorescent focus-based, high-throughput microneutralization test for the respiratory syncytial virus.
The Molecular Diagnostics Sub-Segment is Anticipated to Hold a Considerable Share of the Global Respiratory Syncytial Virus Diagnostic Market
Among the methods, the molecular diagnostics sub-segment is expected to hold a considerable share of the global respiratory syncytical virus diagnosis market. The segmental growth is attributed to the increasing impact of chronic diseases on the global population; respiratory illnesses are projected to grow frequently. This is also anticipated to increase demand for molecular diagnostics in the market for testing infectious diseases like RSV. For instance, in March 2021, GENETWORx Labs announced a diagnostic test that combines the early identification of all three distinct respiratory viruses—Flu A-B, COVID-19, and RSV—in a single test sample for patients. The TCA/GENETWORx Flu A-B/COVID Combo Test is a molecular diagnostic PCR test that identifies influenza A and B viruses and distinguishes them from RSV and SARS-CoV-2, the virus that causes COVID-19. It also detects two types of influenza viruses, influenza A and B.
Regional Outlook
The global respiratory syncytial virus diagnostic market is further segmented based on geography, including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increased burden of respiratory syncytial virus infections in the region. Rise in investments, technical development, product approvals and launches, government efforts, and other major strategies taken by the key market participants. The key players include Jacobson Pharma, Ascletis Pharma Inc., Nuance Pharma, Sino BioogicalInc.,VedaLab and others.
Global Respiratory Syncytial Virus Diagnostic Market Growth, by Region 2023-2030
The North America is Anticipated to Grow at a Significant CAGR in the Global Respiratory Syncytial Virus Diagnostic Market
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to development of modern methods like bio- and nanotechnology (PCR) are helping to develop RSV detection technologies including the western blot, enzyme-linked immunosorbent test (ELISA), direct immunofluorescence, and real-time polymerase chain reaction. In addition, government organizations from many nations provide funding for R&D initiatives to create new treatments.A rise in the number of clinical vaccine studies, an increase in the need for in-vitro diagnostics, an increase in the prevalence of pediatric pneumonia, and a rise in the use of molecular diagnostics are additional factors anticipated to propel the market. These are the specific factors driving market expansion in the region.
Rapid antigen test effectiveness compared to other procedures, increasing product introductions, and significant government and market participant activities are all anticipated to enhance regional growth. Owing to the higher occurrence of RSV infections in babies and young children.According to National Institute of Allergy and Infectious Disease (NIAID), report published in July 2022, According to estimates, RSV infection cause 14,000 death in US adults over 65 each year. RSV is thought to affect 64 million people globally each year, and cause death of 160,000 people globally. With their great specificity, internal checks, and rapid turnaround times, molecular approaches hold promise. Compared to immunoassays in the patient group, molecular diagnostics are becoming more widely used in the region.
Market Players Outlook
The major companies serving the respiratory syncytial virus includes diagnostic market Abbott Laboratories, Bio-Rad Laboratories, Inc., DiaSorin Molecular LLC., NorgenBiotek Corp., Siemens Healthcare Diagnostics Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in Febuaury 2021, BARDA and Luminex Corp. collaborate on a single, rapid diagnostic test to distinguish coronavirus from influenza and RSV infections. With the help of this grant from BARDA, Luminex Corporation will be able to complete the development work necessary to submit an application to the FDA for Emergency Use Authorization (EUA) of the ARIES Flu A/B & RSV+SARS-CoV-2 Assay and to get 510(k) clearance for this combo test.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global respiratory syncytial virus diagnostic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Becton, Dickinson and Company
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. BioMerieux SA
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. F. Hoffmann-La Roche Ltd.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Key Strategy Analysis
4. Market Segmentation
4.1. Global Respiratory Syncytial Virus Diagnostic Market by Product
4.1.1. Kits and Assays
4.1.2. Instruments
4.2. Global Respiratory Syncytial Virus Diagnostic Market by Method
4.2.1. Rapid Antigen Detection Tests
4.2.2. Molecular Diagnostics
4.2.3. Direct Fluorescent Antibody Method
4.2.4. Immunoassays
4.2.5. Others (Flow Cytometry)
4.3. Global Respiratory Syncytial Virus Diagnostic Market by End-Users
4.3.1. Hospitals
4.3.2. Clinics
4.3.3. Laboratories
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Beckman Coulter Inc.
6.3. BioCartis, Hologic, Inc
6.4. Bio-Rad Laboratories, Inc.
6.5. CorisBioConcept
6.6. Danaher
6.7. DiaSorin Molecular LLC.
6.8. Fast Track Diagnostics Luxembourg S.à R.L.
6.9. Luminex Corp.
6.10. Merck KGaA
6.11. NorgenBiotek Corp.
6.12. Ortho Clinical Diagnostics
6.13. Quest Diagnostics
6.14. QuidelOrtho Corporation
6.15. Siemens Healthcare Diagnostics Inc.
6.16. Virax Biolabs
1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
16. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
17. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
18. NORTH AMERICAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
19. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
20. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
21. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
22. EUROPEAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
23. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
24. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
25. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
26. ASIA- PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
27. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
28. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PROUCT, 2022-2030 ($ MILLION)
29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022-2030 ($ MILLION)
30. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022-2030 ($ MILLION)
1. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022 VS 2030 (%)
2. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC KITS AND ASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC INSTRUMRNT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY METHOD, 2022 VS 2030 (%)
5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA RAPID ANTIGEN DETECTION TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA DIRECT FLUORESCENT ANTIBODY METHOD MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC VIA IMMUNOASSAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
9. GLOBAL OTHERS RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY END-USERS, 2022 VS 2030 (%)
11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC IN LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SHARE BY REGION, 2022 VS 2030 (%)
16. US RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
17. CANADA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
18. UK RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
19. FRANCE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
20. GERMANY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
21. ITALY RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
22. SPAIN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
23. REST OF EUROPE RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
24. INDIA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
25. CHINA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
26. JAPAN RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
27. SOUTH KOREA RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
28. REST OF ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
29. REST OF THE WORLD RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTIC MARKET SIZE, 2022-2030 ($ MILLION)
